MeSH term
Frequency | Condition_Probility | Adult | 278 | 0.0 |
Case-Control Studies | 12 | 0.0 |
Comparative Study | 82 | 0.0 |
Female | 224 | 0.0 |
Humans | 536 | 0.0 |
Pituitary Gland/metabolism | 3 | 5.0 |
Probability | 3 | 0.0 |
Prospective Studies | 7 | 0.0 |
Reference Values | 41 | 0.0 |
Research Support, Non-U.S. Gov't | 267 | 0.0 |
Sensitivity and Specificity | 6 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Eating/*physiology | 14 | 20.0 |
Receptors, Cholecystokinin/antagonists & inhibitors/physiology | 3 | 75.0 |
Satiety Response/physiology | 3 | 33.0 |
Aged | 66 | 0.0 |
Aging/*physiology | 2 | 0.0 |
Animals | 191 | 0.0 |
Cholecystokinin/blood | 45 | 84.0 |
Male | 323 | 0.0 |
Cholecystokinin/blood/physiology | 4 | 100.0 |
Eating | 27 | 19.0 |
Leptin/blood/physiology | 2 | 100.0 |
Middle Aged | 128 | 0.0 |
Nutritional Status | 2 | 1.0 |
Obesity/blood | 2 | 5.0 |
*Adaptor Proteins, Signal Transducing | 2 | 0.0 |
Carrier Proteins/metabolism | 2 | 0.0 |
Cell Differentiation | 2 | 0.0 |
Cells, Cultured | 6 | 0.0 |
Gene Deletion | 2 | 0.0 |
Mice | 28 | 0.0 |
Mice, Knockout | 4 | 0.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 26 | 0.0 |
*Signal Transduction | 6 | 0.0 |
Adolescent | 24 | 0.0 |
Analysis of Variance | 9 | 0.0 |
Appetite/drug effects/physiology | 2 | 33.0 |
Cholecystokinin/blood/*secretion | 17 | 100.0 |
Duodenum/*drug effects/physiology | 2 | 100.0 |
Eating/*drug effects/physiology | 2 | 50.0 |
Fat Emulsions, Intravenous/*administration & dosage | 2 | 33.0 |
Feedback | 11 | 5.0 |
Feeding Behavior/*drug effects/physiology | 2 | 33.0 |
Pressure | 15 | 11.0 |
Single-Blind Method | 6 | 2.0 |
Afferent Pathways/physiology | 3 | 15.0 |
*Digestive Physiology | 4 | 12.0 |
Duodenum/innervation | 2 | 100.0 |
*Food | 11 | 12.0 |
Gastric Emptying | 6 | 42.0 |
Research Support, U.S. Gov't, P.H.S. | 97 | 0.0 |
Stomach/innervation | 2 | 66.0 |
Vagus Nerve/physiology | 5 | 25.0 |
Amino Acid Sequence | 29 | 0.0 |
Cholecystokinin/*antagonists & inhibitors | 11 | 100.0 |
Molecular Sequence Data | 29 | 0.0 |
Cholecystokinin/physiology | 8 | 66.0 |
Neurotransmitters/physiology | 3 | 9.0 |
Postprandial Period | 6 | 6.0 |
Receptors, Cholecystokinin/*physiology | 2 | 66.0 |
Serotonin/physiology | 2 | 6.0 |
Signal Transduction/physiology | 2 | 0.0 |
Vagus Nerve/*physiology | 3 | 18.0 |
Central Nervous System/*physiology | 2 | 12.0 |
Cholecystokinin/metabolism | 9 | 60.0 |
Gastrins/metabolism | 6 | 31.0 |
Immunohistochemistry | 5 | 0.0 |
Receptor, Cholecystokinin B | 21 | 58.0 |
Receptors, Cholecystokinin/*biosynthesis | 2 | 100.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Stimulation, Chemical | 9 | 1.0 |
Aged, 80 and over | 19 | 0.0 |
Anorexia/blood/etiology | 2 | 40.0 |
Blood Glucose/analysis | 8 | 1.0 |
Eating/*drug effects | 5 | 25.0 |
Fasting/physiology | 6 | 37.0 |
Hunger/drug effects | 6 | 100.0 |
Injections, Intravenous | 13 | 2.0 |
Insulin/*blood | 4 | 2.0 |
Nausea/etiology | 2 | 33.0 |
Osmolar Concentration | 4 | 0.0 |
Satiety Response/drug effects | 3 | 75.0 |
Child | 4 | 0.0 |
Questionnaires | 5 | 0.0 |
Risk Factors | 5 | 0.0 |
Time Factors | 39 | 0.0 |
Gene Expression | 7 | 0.0 |
Molecular Weight | 5 | 0.0 |
RNA, Messenger/genetics/metabolism | 2 | 0.0 |
Receptor, Cholecystokinin A | 25 | 78.0 |
Receptors, Cholecystokinin/genetics/*metabolism | 4 | 100.0 |
Gastrins/*pharmacology | 2 | 12.0 |
In Situ Hybridization | 5 | 0.0 |
In Vitro | 25 | 0.0 |
RNA, Messenger/metabolism | 3 | 0.0 |
Sincalide/*pharmacology | 6 | 60.0 |
Protein Processing, Post-Translational | 4 | 0.0 |
Eating/physiology | 9 | 16.0 |
Gastric Acid/*secretion | 11 | 18.0 |
Gastrins/secretion | 6 | 46.0 |
*Helicobacter pylori | 3 | 2.0 |
Administration, Oral | 11 | 1.0 |
Area Under Curve | 5 | 1.0 |
Cholecystokinin/*blood | 77 | 98.0 |
Energy Intake/physiology | 2 | 7.0 |
Enzyme Inhibitors/*pharmacology | 4 | 0.0 |
Gastric Inhibitory Polypeptide/blood | 2 | 5.0 |
Glucagon/*blood | 3 | 16.0 |
Insulin/blood | 15 | 2.0 |
Peptide Fragments/*blood | 3 | 3.0 |
Peptide YY/blood | 7 | 70.0 |
Protein Precursors/*blood | 4 | 5.0 |
Alleles | 7 | 0.0 |
Body Weight | 7 | 1.0 |
Cholecystokinin/*genetics | 17 | 85.0 |
Genotype | 6 | 0.0 |
Models, Biological | 3 | 0.0 |
Polymorphism, Genetic/genetics | 2 | 0.0 |
Reproducibility of Results | 2 | 0.0 |
Animals, Newborn | 2 | 0.0 |
Benzodiazepinones/pharmacology | 10 | 55.0 |
Cholecystokinin/metabolism/*physiology | 5 | 100.0 |
Devazepide/pharmacology | 4 | 100.0 |
Phenylurea Compounds/pharmacology | 2 | 33.0 |
Rats | 72 | 0.0 |
Rats, Sprague-Dawley | 13 | 0.0 |
Receptors, Cholecystokinin/antagonists & inhibitors/*metabolism | 3 | 100.0 |
*Appetite | 3 | 60.0 |
Cholecystokinin/*physiology | 26 | 100.0 |
Eating Disorders | 2 | 66.0 |
*Feeding Behavior | 4 | 57.0 |
Stomach/metabolism | 2 | 5.0 |
Brain/metabolism | 4 | 0.0 |
Feeding Behavior | 2 | 8.0 |
Hypothalamus/metabolism | 3 | 6.0 |
Satiation | 6 | 75.0 |
Signal Transduction | 5 | 0.0 |
Base Sequence | 12 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
*Promoter Regions (Genetics) | 5 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
*Transcription, Genetic | 2 | 0.0 |
Transfection | 6 | 0.0 |
Tumor Cells, Cultured | 13 | 0.0 |
Panic Disorder/*genetics | 3 | 23.0 |
*Polymorphism, Genetic | 4 | 0.0 |
Schizophrenia/*genetics | 2 | 0.0 |
Chromatography, High Pressure Liquid | 6 | 0.0 |
Hydrolysis | 2 | 0.0 |
Indicators and Reagents | 4 | 1.0 |
Kinetics | 24 | 0.0 |
Caerulein/diagnostic use | 2 | 100.0 |
Follow-Up Studies | 3 | 0.0 |
Gallbladder/physiology/ultrasonography | 2 | 100.0 |
Intubation, Gastrointestinal | 8 | 66.0 |
Parenteral Nutrition, Total | 4 | 23.0 |
Corn Oil/administration & dosage | 2 | 40.0 |
Administration, Intranasal | 2 | 2.0 |
Cross-Over Studies | 17 | 2.0 |
Electroencephalography/drug effects | 3 | 12.0 |
Dietary Carbohydrates/*administration & dosage | 2 | 8.0 |
Dietary Fats/*administration & dosage | 6 | 7.0 |
Gastrointestinal Motility/*physiology | 5 | 31.0 |
Manometry | 9 | 25.0 |
Multivariate Analysis | 3 | 0.0 |
Postprandial Period/*physiology | 2 | 6.0 |
Stomach/drug effects/*physiology | 2 | 66.0 |
Cholecystokinin/*secretion | 8 | 80.0 |
Severity of Illness Index | 2 | 0.0 |
Gastric Emptying/drug effects/*physiology | 4 | 100.0 |
Gastrins/blood | 18 | 24.0 |
Gastroscopy | 2 | 4.0 |
Treatment Outcome | 4 | 0.0 |
Amino Acids/administration & dosage/blood/*pharmacology | 2 | 100.0 |
Compliance | 2 | 12.0 |
Gastrointestinal Motility/*drug effects/physiology | 6 | 100.0 |
Infusions, Intravenous | 26 | 3.0 |
Peptide Fragments/blood | 4 | 3.0 |
Stomach/*drug effects/physiology | 3 | 75.0 |
Digestion/physiology | 2 | 25.0 |
Enteral Nutrition | 6 | 25.0 |
Hunger/physiology | 3 | 33.0 |
Anthropometry | 2 | 0.0 |
Blood Glucose | 4 | 4.0 |
Energy Intake | 7 | 3.0 |
Fatty Acids, Nonesterified/blood | 3 | 1.0 |
Glycerol/blood | 2 | 5.0 |
Double-Blind Method | 25 | 1.0 |
Energy Intake/*drug effects | 3 | 75.0 |
Hormone Antagonists/*pharmacology | 4 | 16.0 |
Random Allocation | 3 | 0.0 |
Receptors, Cholecystokinin/antagonists & inhibitors/*physiology | 5 | 100.0 |
Satiation/*drug effects/physiology | 3 | 75.0 |
Hospitalization | 2 | 1.0 |
Pancreatitis/*blood | 6 | 35.0 |
Sphincter of Oddi/*physiology | 3 | 100.0 |
Dose-Response Relationship, Drug | 30 | 0.0 |
Duodenum/metabolism | 10 | 27.0 |
Intestines/metabolism | 4 | 3.0 |
Neurotensin/blood | 2 | 28.0 |
Pancreatic Polypeptide/blood | 25 | 42.0 |
Postprandial Period/physiology | 4 | 22.0 |
Gallbladder Emptying/*drug effects/physiology | 2 | 100.0 |
Gastric Emptying/*drug effects/physiology | 3 | 100.0 |
*Gallbladder Emptying | 2 | 100.0 |
Diet | 7 | 1.0 |
Gastrins/pharmacology | 5 | 41.0 |
Gene Expression/physiology | 2 | 0.0 |
Hormone Antagonists/pharmacology | 15 | 23.0 |
Proglumide/*analogs & derivatives/pharmacology | 19 | 100.0 |
RNA, Messenger/analysis | 3 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Sincalide/pharmacology | 15 | 83.0 |
Gastric Emptying/physiology | 5 | 27.0 |
Pain Measurement | 2 | 2.0 |
Gallbladder Emptying/*physiology | 5 | 62.0 |
Gastrointestinal Hormones/*blood | 4 | 4.0 |
Cell Count | 2 | 0.0 |
Cholecystokinin/genetics/metabolism | 2 | 66.0 |
Dopamine/*metabolism | 2 | 1.0 |
Exons/genetics | 2 | 0.0 |
Neuropeptides/genetics | 2 | 9.0 |
Substantia Nigra/cytology/*metabolism | 2 | 22.0 |
Digestion/*physiology | 5 | 41.0 |
*Gabexate/*analogs & derivatives | 4 | 80.0 |
Guanidines/pharmacology | 2 | 4.0 |
Phosphorylation/drug effects | 2 | 0.0 |
Cholecystokinin/pharmacology | 4 | 25.0 |
Enzyme Activation | 3 | 0.0 |
Membrane Potentials | 2 | 0.0 |
Trypsin/*metabolism | 3 | 14.0 |
Appetite Regulation/drug effects/*physiology | 2 | 66.0 |
Cholecystokinin/pharmacology/*physiology | 4 | 80.0 |
Eating/drug effects/*physiology | 3 | 37.0 |
Obesity/*physiopathology | 4 | 7.0 |
Appetite/*drug effects | 5 | 62.0 |
Emulsions | 2 | 2.0 |
Fat Emulsions, Intravenous/administration & dosage/*pharmacology | 2 | 40.0 |
Hunger | 3 | 60.0 |
Infusions, Parenteral | 8 | 5.0 |
Oleic Acid/administration & dosage/pharmacology | 2 | 100.0 |
Chronic Disease | 20 | 1.0 |
*Food, Formulated | 6 | 31.0 |
Receptors, Cholecystokinin/agonists/antagonists & inhibitors/*metabolism | 3 | 100.0 |
Cyclic AMP/*metabolism | 3 | 1.0 |
Mitogen-Activated Protein Kinases/*metabolism | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Polymerase Chain Reaction | 5 | 0.0 |
Polymorphism, Genetic | 3 | 0.0 |
Body Mass Index | 6 | 0.0 |
Luteinizing Hormone/blood | 2 | 0.0 |
Neuropeptide Y/*blood | 2 | 2.0 |
Dynorphins/physiology | 3 | 100.0 |
Morphine/pharmacology | 3 | 21.0 |
Pain/*etiology | 2 | 25.0 |
Cholecystokinin/*metabolism | 13 | 76.0 |
Pancreas/metabolism | 6 | 6.0 |
Receptors, Cholecystokinin/*metabolism | 9 | 64.0 |
Amylases/secretion | 13 | 72.0 |
Duodenum/enzymology | 3 | 37.0 |
Food | 27 | 23.0 |
Lipase/secretion | 6 | 66.0 |
Pancreas/*enzymology/secretion | 3 | 100.0 |
Pancreatic Function Tests/*methods | 2 | 100.0 |
Trypsin/secretion | 9 | 81.0 |
Placebos | 3 | 1.0 |
Acute Disease | 10 | 0.0 |
Cholecystokinin/*pharmacology | 19 | 76.0 |
Feeding Behavior/*drug effects | 5 | 31.0 |
Peptides/pharmacology | 4 | 2.0 |
Appetite/*physiology | 2 | 15.0 |
Gallbladder/drug effects/physiology | 3 | 75.0 |
Cohort Studies | 4 | 0.0 |
Polymorphism, Restriction Fragment Length | 2 | 0.0 |
Receptors, Cholecystokinin/*genetics | 3 | 30.0 |
Gastrointestinal Transit | 3 | 60.0 |
Intestinal Absorption | 2 | 1.0 |
Radioimmunoassay | 66 | 3.0 |
Autoradiography | 10 | 1.0 |
RNA, Messenger/*biosynthesis | 2 | 0.0 |
Schizophrenia/*metabolism | 2 | 11.0 |
Amino Acid Substitution | 2 | 0.0 |
Binding Sites | 9 | 0.0 |
COS Cells | 3 | 0.0 |
Computer Simulation | 2 | 0.0 |
Iodine Radioisotopes | 7 | 1.0 |
Models, Molecular | 2 | 0.0 |
Mutagenesis, Site-Directed | 4 | 0.0 |
Protein Conformation | 3 | 0.0 |
Radioligand Assay | 6 | 1.0 |
Receptors, Cholecystokinin/*chemistry/*metabolism | 2 | 100.0 |
Amylases/blood | 2 | 9.0 |
Brain/*metabolism | 6 | 1.0 |
Cholecystokinin/*cerebrospinal fluid | 2 | 100.0 |
Temperance | 2 | 16.0 |
Protein Binding | 2 | 0.0 |
Imino Acids/diagnostic use | 2 | 100.0 |
Organotechnetium Compounds/diagnostic use | 2 | 18.0 |
Cholecystectomy | 3 | 16.0 |
Gastrectomy | 2 | 3.0 |
Gallbladder/anatomy & histology/*physiology | 3 | 100.0 |
Pancreatic Polypeptide/blood/secretion | 4 | 57.0 |
Duodenum/*physiology | 4 | 36.0 |
*Enteral Nutrition | 3 | 12.0 |
Fasting | 15 | 4.0 |
Gastrointestinal Transit/*physiology | 2 | 100.0 |
Intestine, Small/*physiology | 2 | 50.0 |
Stomach/*physiology | 3 | 42.0 |
Species Specificity | 12 | 0.0 |
Swine | 8 | 0.0 |
CHO Cells | 3 | 0.0 |
Hamsters | 7 | 0.0 |
Receptors, Cholecystokinin/*antagonists & inhibitors | 14 | 87.0 |
Structure-Activity Relationship | 10 | 0.0 |
Feedback/physiology | 3 | 12.0 |
Peptide YY/*blood | 2 | 66.0 |
Retrospective Studies | 3 | 0.0 |
Cell Membrane/metabolism | 4 | 0.0 |
Cholesterol/*metabolism | 2 | 0.0 |
Sincalide/metabolism/pharmacology | 2 | 100.0 |
Anti-Obesity Agents/pharmacology | 2 | 100.0 |
Gastric Emptying/drug effects | 7 | 63.0 |
Lactones/*pharmacology | 3 | 10.0 |
Lipase/*antagonists & inhibitors | 4 | 50.0 |
Satiation/drug effects | 2 | 100.0 |
Ligands | 9 | 0.0 |
Duodenum | 8 | 32.0 |
Glucose/pharmacology | 3 | 2.0 |
Bicarbonates/metabolism | 4 | 21.0 |
Blood Glucose/metabolism | 8 | 1.0 |
Drug Synergism | 6 | 0.0 |
Proteins/secretion | 2 | 22.0 |
Secretin/*pharmacology | 4 | 33.0 |
Calcium/metabolism | 6 | 0.0 |
Cell Division/drug effects | 2 | 0.0 |
Pancreatic Neoplasms/metabolism/*pathology | 2 | 6.0 |
Peptoids | 2 | 33.0 |
Receptors, Cholecystokinin/*drug effects/metabolism | 2 | 100.0 |
Gastrins/*metabolism | 4 | 25.0 |
Sequence Homology, Amino Acid | 4 | 0.0 |
*Gastric Emptying | 3 | 30.0 |
Pancreatic Neoplasms/etiology | 2 | 100.0 |
Postoperative Period | 4 | 1.0 |
Pancreas/enzymology | 3 | 8.0 |
Bilirubin/secretion | 4 | 100.0 |
Cholecystokinin/blood/*pharmacology | 9 | 100.0 |
Glucose Clamp Technique | 2 | 1.0 |
Pancreas/*secretion | 16 | 76.0 |
Disease Models, Animal | 3 | 0.0 |
Dietary Fats/metabolism | 3 | 9.0 |
Dietary Proteins/metabolism | 2 | 22.0 |
English Abstract | 25 | 0.0 |
Gallbladder Emptying/physiology | 2 | 100.0 |
Gastrointestinal Motility/*drug effects | 8 | 36.0 |
Proglumide/analogs & derivatives/pharmacology | 21 | 84.0 |
Pyloric Antrum/drug effects/physiology | 2 | 100.0 |
Receptors, Cholecystokinin/antagonists & inhibitors | 18 | 90.0 |
Duodenum/drug effects/*physiology | 2 | 100.0 |
Hormones/blood | 4 | 3.0 |
Pylorus/physiology | 3 | 100.0 |
Somatostatin/metabolism | 3 | 6.0 |
Cholecystokinin/antagonists & inhibitors/blood/*physiology | 4 | 100.0 |
Gestational Age | 3 | 0.0 |
Infant, Newborn | 5 | 0.0 |
Parasympathetic Nervous System/physiology | 2 | 25.0 |
Somatostatin/*blood | 5 | 27.0 |
Bilirubin/metabolism | 4 | 20.0 |
Bombesin/*pharmacology | 7 | 38.0 |
Duodenum/*metabolism | 5 | 26.0 |
Trypsin/metabolism | 6 | 4.0 |
Drug Administration Schedule | 2 | 0.0 |
Maze Learning/drug effects | 2 | 22.0 |
Mutation | 2 | 0.0 |
Amylases/metabolism | 8 | 42.0 |
Cholecystokinin/*physiology/secretion | 2 | 100.0 |
Cholestyramine/*pharmacology | 3 | 60.0 |
Gallbladder/physiology | 4 | 80.0 |
Hydrogen-Ion Concentration | 19 | 1.0 |
Muscle Contraction/drug effects | 15 | 16.0 |
Muscle, Smooth/drug effects/physiology | 4 | 44.0 |
Biliary Tract/drug effects/*secretion | 2 | 100.0 |
Pancreas/drug effects/*secretion | 4 | 57.0 |
Dietary Fats/pharmacology | 2 | 5.0 |
Duodenum/*drug effects | 3 | 60.0 |
Gallbladder/ultrasonography | 5 | 100.0 |
Brain/physiology | 2 | 3.0 |
Satiety Response/*physiology | 6 | 75.0 |
Vagotomy | 2 | 14.0 |
Binding, Competitive | 8 | 0.0 |
Gastric Acid/secretion | 5 | 11.0 |
Gastrins/*antagonists & inhibitors | 2 | 100.0 |
Biological Markers/blood | 2 | 0.0 |
Cross-Sectional Studies | 3 | 0.0 |
Phosphatidylinositols/metabolism | 3 | 2.0 |
Arousal/physiology | 2 | 9.0 |
Gastrins/*blood | 7 | 16.0 |
DNA Mutational Analysis | 2 | 0.0 |
Promoter Regions (Genetics)/*genetics | 3 | 0.0 |
Transcription Factor, Sp1/*genetics | 2 | 4.0 |
Variation (Genetics) | 2 | 0.0 |
Gene Frequency | 2 | 0.0 |
Glucagon/blood | 3 | 3.0 |
Hydrocortisone/blood | 2 | 0.0 |
Clinical Trials | 4 | 0.0 |
Metabolic Clearance Rate | 3 | 0.0 |
Receptors, Cholecystokinin | 9 | 100.0 |
Dietary Fats/administration & dosage | 7 | 8.0 |
Inositol 1,4,5-Trisphosphate/metabolism | 2 | 3.0 |
Iodine Radioisotopes/diagnostic use | 6 | 1.0 |
Sincalide/analogs & derivatives/pharmacology | 4 | 100.0 |
Cholecystokinin/*blood/secretion | 5 | 100.0 |
Gallbladder Emptying/*drug effects | 7 | 100.0 |
Intestinal Mucosa/metabolism/pathology | 2 | 6.0 |
Cholecystokinin/biosynthesis/*genetics | 3 | 100.0 |
*Exons | 2 | 0.0 |
Amino Acids/administration & dosage/*pharmacology | 5 | 71.0 |
Cholecystokinin/blood/*physiology | 9 | 100.0 |
Gallbladder/drug effects/*physiology/ultrasonography | 3 | 100.0 |
Proglumide/administration & dosage/analogs & derivatives/pharmacology | 2 | 100.0 |
Mitogen-Activated Protein Kinase 3 | 2 | 0.0 |
Signal Transduction/drug effects/physiology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 2 | 0.0 |
ras Proteins/metabolism | 2 | 1.0 |
Bile/chemistry | 2 | 33.0 |
Rats, Wistar | 3 | 0.0 |
Taurocholic Acid/pharmacology | 2 | 22.0 |
Food, Formulated | 9 | 30.0 |
Organ Specificity | 6 | 0.0 |
Protein Precursors/metabolism | 3 | 2.0 |
Gastric Emptying/drug effects/physiology | 2 | 100.0 |
Cholecystokinin/biosynthesis/*blood | 2 | 100.0 |
Diabetes Mellitus, Type 2/blood/*physiopathology | 2 | 10.0 |
*Diet | 4 | 1.0 |
Liver/metabolism | 2 | 0.0 |
Gallbladder Emptying/drug effects/*physiology | 4 | 80.0 |
Hemodynamic Processes/drug effects | 2 | 1.0 |
Sincalide/*administration & dosage | 2 | 100.0 |
Interleukin-1/*pharmacology | 2 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Gallbladder/drug effects/secretion | 2 | 100.0 |
Gastric Emptying/*drug effects | 7 | 53.0 |
Pancreas/drug effects/secretion | 2 | 50.0 |
Digestion | 3 | 23.0 |
Nutrition | 2 | 5.0 |
Calcium/*metabolism | 4 | 0.0 |
Pancreas/cytology/*metabolism | 2 | 33.0 |
Chymotrypsin/secretion | 5 | 100.0 |
Pancreas/*enzymology | 6 | 15.0 |
Secretin/blood | 4 | 40.0 |
Gallbladder/*physiopathology | 6 | 100.0 |
Gastric Acid/metabolism | 2 | 40.0 |
Parasympathetic Nervous System/*physiology | 2 | 14.0 |
Dietary Fats | 2 | 5.0 |
Muscle Relaxation/*drug effects | 2 | 33.0 |
Proglumide/administration & dosage/*analogs & derivatives/pharmacology | 5 | 100.0 |
Colon/*physiology | 2 | 25.0 |
Gastrointestinal Motility/drug effects/*physiology | 2 | 66.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Fluorescent Dyes | 2 | 0.0 |
Neuroblastoma | 2 | 1.0 |
Phosphorylation | 3 | 0.0 |
Chromatography, Gel | 7 | 0.0 |
Sincalide/metabolism | 5 | 62.0 |
Bilirubin/blood | 2 | 2.0 |
Monitoring, Physiologic | 2 | 2.0 |
Brain Mapping | 4 | 2.0 |
*Schizophrenic Psychology | 4 | 6.0 |
Cholecystokinin/genetics/*metabolism/physiology | 2 | 100.0 |
Sincalide/analogs & derivatives/metabolism | 3 | 75.0 |
Caerulein/pharmacology | 11 | 84.0 |
Muscle Contraction | 6 | 11.0 |
Perfusion | 3 | 1.0 |
Cholecystokinin/secretion | 4 | 80.0 |
Gallbladder/drug effects/*physiology | 5 | 100.0 |
Receptors, Muscarinic/drug effects/*physiology | 2 | 33.0 |
Atrophy | 2 | 1.0 |
DNA Probes | 2 | 0.0 |
Genomic Library | 2 | 0.0 |
Cholecystokinin/*antagonists & inhibitors/physiology | 3 | 100.0 |
Sincalide/*analogs & derivatives/pharmacology | 2 | 66.0 |
Diabetes Mellitus, Type 2/*physiopathology | 2 | 6.0 |
Dietary Carbohydrates | 2 | 8.0 |
Dietary Proteins | 2 | 14.0 |
*Gastric Emptying/drug effects | 2 | 100.0 |
*Intestinal Absorption | 2 | 5.0 |
Gastric Emptying/*physiology | 3 | 50.0 |
Arousal/*drug effects | 2 | 40.0 |
Brain/*drug effects | 2 | 12.0 |
Benzodiazepines/*pharmacology | 2 | 20.0 |
Receptors, Cholecystokinin/*antagonists & inhibitors/physiology | 4 | 100.0 |
Cholecystokinin/blood/*metabolism | 6 | 100.0 |
Atropine/pharmacology | 10 | 25.0 |
Duodenum/drug effects/physiology | 2 | 100.0 |
Cattle | 3 | 0.0 |
*Phenylurea Compounds | 6 | 85.0 |
Hybrid Cells | 2 | 0.0 |
Somatostatin/*metabolism | 2 | 8.0 |
Piperidines/*pharmacology | 2 | 3.0 |
Carboxypeptidases/metabolism | 2 | 10.0 |
Pancreas/*drug effects/secretion | 3 | 60.0 |
Trypsin/*secretion | 3 | 100.0 |
Trypsin Inhibitors/*pharmacology | 3 | 42.0 |
*Protein Processing, Post-Translational | 2 | 0.0 |
Anti-Anxiety Agents/*pharmacology | 2 | 14.0 |
Tetragastrin/pharmacology | 2 | 50.0 |
Diabetes Mellitus, Type 2/*blood | 2 | 1.0 |
Receptors, Cholecystokinin/drug effects | 4 | 80.0 |
Birth Weight | 2 | 1.0 |
Infant, Premature/*blood | 2 | 6.0 |
Pregnancy | 2 | 0.0 |
Culture Techniques | 3 | 0.0 |
Anxiety Disorders/*physiopathology | 2 | 100.0 |
Callithrix | 2 | 2.0 |
Guinea Pigs | 10 | 1.0 |
Guanosine 5'-O-(3-Thiotriphosphate)/pharmacology | 2 | 2.0 |
Cholecystokinin/antagonists & inhibitors/*physiology | 8 | 80.0 |
Gastrins/blood/*metabolism | 2 | 100.0 |
Receptors, Cholecystokinin/physiology | 4 | 66.0 |
*Growth Substances | 2 | 11.0 |
*Intercellular Signaling Peptides and Proteins | 2 | 0.0 |
Blotting, Northern | 3 | 0.0 |
Transcription, Genetic | 2 | 0.0 |
Somatostatin/blood | 3 | 12.0 |
Duodenal Ulcer/*physiopathology | 3 | 33.0 |
Evaluation Studies | 2 | 0.0 |
Sex Distribution | 2 | 0.0 |
Corn Oil/pharmacology | 3 | 42.0 |
Immune Sera/immunology | 2 | 1.0 |
Dietary Fats/administration & dosage/*pharmacology | 3 | 23.0 |
Pancreatic Polypeptide/metabolism | 2 | 9.0 |
Bile/*physiology | 3 | 30.0 |
Cholestasis/blood/etiology | 2 | 100.0 |
Lipase/metabolism | 4 | 7.0 |
Pancreatitis/*metabolism | 2 | 18.0 |
Satiation/*drug effects | 6 | 100.0 |
Devazepide | 18 | 94.0 |
Cholecystokinin/administration & dosage/*pharmacology | 2 | 100.0 |
Cholesterol/analysis | 2 | 4.0 |
Gallbladder/*physiopathology/ultrasonography | 3 | 100.0 |
Cholecystokinin/administration & dosage/blood/*pharmacology | 2 | 100.0 |
Esophagogastric Junction/*drug effects/physiology | 2 | 50.0 |
Gallbladder/*drug effects/physiology | 7 | 100.0 |
Somatostatin/*secretion | 2 | 25.0 |
Cell Line | 6 | 0.0 |
Dogs | 14 | 1.0 |
Temperature | 3 | 0.0 |
Digestive Physiology | 4 | 17.0 |
Digestive System/drug effects | 5 | 45.0 |
Pylorus/surgery | 2 | 66.0 |
Benzodiazepinones/*pharmacology | 6 | 50.0 |
Kidney/metabolism | 2 | 0.0 |
Radioimmunoassay/methods | 14 | 9.0 |
Dietary Fats/*pharmacology | 5 | 7.0 |
Pancreatic Polypeptide/secretion | 3 | 37.0 |
Somatostatin/secretion | 2 | 18.0 |
Drug Interactions | 4 | 0.0 |
Homeostasis | 2 | 0.0 |
Hormones/pharmacology | 3 | 6.0 |
Benzodiazepinones/metabolism | 2 | 66.0 |
Peptide Fragments/*metabolism | 2 | 1.0 |
Sincalide/*metabolism | 2 | 66.0 |
Cholecystokinin/*antagonists & inhibitors/blood | 2 | 100.0 |
Eating/drug effects | 4 | 10.0 |
Fat Emulsions, Intravenous/*pharmacology | 4 | 33.0 |
Chymotrypsin/antagonists & inhibitors | 2 | 20.0 |
Gastric Mucosa/drug effects | 3 | 50.0 |
Satiation/drug effects/*physiology | 2 | 100.0 |
Ileum/drug effects/physiology | 2 | 100.0 |
Glucose/administration & dosage | 2 | 6.0 |
Infant | 3 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Pancreatic Polypeptide/blood/*secretion | 2 | 25.0 |
Nervous System/metabolism | 2 | 9.0 |
Receptors, Cholecystokinin/metabolism | 3 | 42.0 |
Neoplasm Transplantation | 5 | 0.0 |
Pancreatic Neoplasms/*metabolism/pathology | 2 | 4.0 |
Drug Tolerance | 3 | 2.0 |
Central Nervous System/drug effects | 2 | 25.0 |
Behavior, Animal/*physiology | 2 | 7.0 |
Half-Life | 4 | 0.0 |
Depression, Chemical | 2 | 1.0 |
Duodenum/*physiopathology | 2 | 100.0 |
Chromosome Banding | 2 | 0.0 |
Chromosome Mapping | 3 | 0.0 |
Hunger/*physiology | 2 | 100.0 |
Satiation/*physiology | 3 | 60.0 |
Injections, Intraperitoneal | 2 | 1.0 |
Receptors, Cholecystokinin/drug effects/physiology | 2 | 100.0 |
Pancreatic Neoplasms/complications | 2 | 28.0 |
Muscle Contraction/drug effects/*physiology | 3 | 37.0 |
Gastrins/*secretion | 2 | 28.0 |
Cholecystokinin/*blood/isolation & purification | 2 | 100.0 |
Immune Sera | 5 | 1.0 |
Duodenum/physiology | 3 | 37.0 |
Haplorhini | 4 | 1.0 |
*Satiation | 2 | 100.0 |
Oligonucleotide Probes | 3 | 0.0 |
Protein Precursors/genetics | 3 | 3.0 |
Gastrointestinal Motility | 2 | 13.0 |
Amylases/analysis | 2 | 33.0 |
Carbachol/pharmacology | 4 | 4.0 |
Cholecystokinin/*blood/pharmacology | 4 | 100.0 |
Organ Size | 4 | 2.0 |
Secretin/*blood | 2 | 40.0 |
Iodine Radioisotopes/metabolism | 2 | 5.0 |
Secretin/pharmacology | 5 | 22.0 |
Substance P/pharmacology | 2 | 6.0 |
Vasoactive Intestinal Peptide/pharmacology | 2 | 2.0 |
Dietary Proteins/*pharmacology | 3 | 23.0 |
Biological Assay | 3 | 1.0 |
Cholecystokinin/antagonists & inhibitors/*blood | 2 | 100.0 |
Proglumide/pharmacology | 3 | 100.0 |
Pancreas/drug effects/enzymology/*secretion | 3 | 100.0 |
Heart Rate/drug effects | 2 | 0.0 |
Gastrin-Releasing Peptide | 3 | 3.0 |
Mice, Transgenic | 2 | 0.0 |
Antibody Specificity | 6 | 0.0 |
Rats, Inbred Strains | 15 | 1.0 |
RNA, Messenger/genetics | 3 | 0.0 |
*Gastrointestinal Motility | 3 | 30.0 |
Gallbladder/*drug effects/physiopathology | 2 | 100.0 |
Gastrointestinal Diseases/*drug therapy/physiopathology | 2 | 100.0 |
Pancreas/*drug effects/physiopathology | 2 | 100.0 |
Sphincter of Oddi/*drug effects/physiopathology | 2 | 100.0 |
Bile Acids and Salts/secretion | 3 | 50.0 |
Pancreas/pathology | 2 | 5.0 |
Cholecystokinin/blood/pharmacology/*secretion | 2 | 100.0 |
*Radioimmunoassay | 2 | 5.0 |
Dietary Fiber/*administration & dosage | 2 | 12.0 |
Gallbladder Emptying/drug effects | 2 | 100.0 |
Triglycerides/blood | 2 | 0.0 |
Image Processing, Computer-Assisted | 2 | 0.0 |
Nucleic Acid Hybridization | 3 | 0.0 |
Cholecystokinin/*antagonists & inhibitors/blood/physiology | 2 | 100.0 |
Pancreatic Polypeptide/*blood | 5 | 25.0 |
Receptors, Cholecystokinin/*drug effects | 6 | 100.0 |
Adenocarcinoma/*drug therapy | 2 | 14.0 |
Analgesia | 3 | 37.0 |
Energy Metabolism/physiology | 3 | 5.0 |
Feces | 2 | 13.0 |
Bombesin/pharmacology | 3 | 20.0 |
Biological Assay/*methods | 3 | 7.0 |
Pancreas/secretion | 3 | 42.0 |
Pancreas/*physiology | 3 | 37.0 |
Gastrointestinal Hormones/*metabolism | 3 | 12.0 |
Hormones/*blood | 2 | 1.0 |
*Gastrectomy | 6 | 25.0 |
Gallbladder/*drug effects | 4 | 100.0 |
Pancreas/*drug effects/enzymology/secretion | 3 | 100.0 |
Secretin/blood/pharmacology | 2 | 100.0 |
Trypsin/analysis | 2 | 40.0 |
Alzheimer Disease/*metabolism | 3 | 1.0 |
*Brain Chemistry | 4 | 2.0 |
Cholecystokinin/*analysis | 4 | 80.0 |
Histocytochemistry | 3 | 0.0 |
Receptors, Cholecystokinin/*analysis | 3 | 50.0 |
Exons | 2 | 0.0 |
Pancreatic Polypeptide/*secretion | 2 | 40.0 |
Muscle Contraction/*drug effects | 2 | 8.0 |
Diabetes Complications | 2 | 1.0 |
Appetite/drug effects | 2 | 33.0 |
Atropine/*pharmacology | 7 | 38.0 |
Cholecystokinin/blood/pharmacology | 2 | 100.0 |
Glutamine/*analogs & derivatives | 8 | 100.0 |
Secretory Rate/drug effects | 3 | 3.0 |
Chromatography, High Pressure Liquid/methods | 3 | 2.0 |
Intestinal Mucosa/analysis | 2 | 50.0 |
DNA/metabolism | 2 | 0.0 |
Mice, Nude | 3 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Blotting, Western | 2 | 0.0 |
Brain Chemistry | 2 | 0.0 |
Electrophoresis, Polyacrylamide Gel | 2 | 0.0 |
Precipitin Tests | 2 | 0.0 |
Protein Biosynthesis | 4 | 0.0 |
Bile Acids and Salts/*secretion | 2 | 66.0 |
Cholecystokinin/genetics/*metabolism | 2 | 100.0 |
RNA, Messenger/*metabolism | 2 | 0.0 |
Peptones/pharmacology | 2 | 50.0 |
Muscle, Smooth/drug effects | 3 | 15.0 |
Propranolol/pharmacology | 2 | 4.0 |
Bombesin/antagonists & inhibitors/*pharmacology | 2 | 100.0 |
*Analgesia | 2 | 16.0 |
Caerulein/*pharmacology | 3 | 100.0 |
Proglumide/*pharmacology | 2 | 100.0 |
Ultrasonography | 3 | 3.0 |
Sincalide/blood | 3 | 100.0 |
Brain/*physiology | 2 | 1.0 |
Gallbladder/*physiology | 7 | 77.0 |
*Eating | 4 | 6.0 |
Gallbladder/drug effects/*physiopathology | 2 | 100.0 |
Muscle, Smooth/*drug effects | 2 | 13.0 |
Immunoenzyme Techniques | 2 | 0.0 |
Neuropeptides/*analysis | 2 | 2.0 |
Drug Therapy, Combination | 2 | 0.0 |
Schizophrenia/*drug therapy | 2 | 6.0 |
Affinity Labels | 2 | 3.0 |
Chemical Fractionation | 2 | 2.0 |
Histamine/pharmacology | 2 | 3.0 |
Succinimides/metabolism | 3 | 27.0 |
Stomach/physiology | 2 | 25.0 |
Cholesterol/blood | 2 | 0.0 |
Pancreatic Juice/*secretion | 4 | 80.0 |
Cholecystokinin/*diagnostic use | 2 | 100.0 |
Amino Acids/*pharmacology | 2 | 8.0 |
Aprotinin/pharmacology | 2 | 9.0 |
Cholecystokinin/administration & dosage/blood/*physiology | 2 | 100.0 |
Protease Inhibitors/*pharmacology | 2 | 4.0 |
Pancreatic Function Tests | 2 | 18.0 |
Secretin/diagnostic use | 2 | 33.0 |
Tissue Distribution | 4 | 0.0 |
Motilin/blood | 3 | 16.0 |
Pancreatic Juice/secretion | 2 | 40.0 |
Cholecystokinin/*immunology | 2 | 100.0 |
Antigen-Antibody Complex | 2 | 1.0 |
Glucagon/pharmacology | 2 | 6.0 |
Insulin/*secretion | 2 | 2.0 |
Neuropeptides/analysis/*physiology | 2 | 66.0 |
Neurotransmitters/*physiology | 2 | 6.0 |
Fat Emulsions, Intravenous/pharmacology | 2 | 25.0 |
Triglycerides/*pharmacology | 2 | 33.0 |
Chemistry | 3 | 1.0 |
Molecular Conformation | 3 | 1.0 |
Synaptic Transmission | 2 | 5.0 |
Pancreas/physiopathology | 2 | 22.0 |
Bicarbonates/secretion | 3 | 75.0 |
Oleic Acid | 4 | 6.0 |
Oleic Acids/pharmacology | 3 | 14.0 |
Phenylalanine/pharmacology | 2 | 50.0 |
Pancreas/*drug effects | 2 | 40.0 |
Vasoactive Intestinal Peptide/blood | 2 | 4.0 |
Circadian Rhythm | 2 | 0.0 |
Genes, Structural | 4 | 0.0 |
Oleic Acids/*pharmacology | 2 | 13.0 |
Endorphins/physiology | 2 | 16.0 |
Receptors, Cell Surface/*metabolism | 4 | 0.0 |
Receptors, Cell Surface/physiology | 2 | 1.0 |
beta-Endorphin | 3 | 13.0 |
Amino Acids/pharmacology | 3 | 15.0 |
Peptide Fragments/pharmacology | 2 | 0.0 |
Rabbits | 5 | 0.0 |
Sheep | 2 | 0.0 |
Ampulla of Vater/*physiology | 2 | 100.0 |
Cross Reactions | 3 | 0.0 |
Cerebral Cortex/*metabolism | 3 | 5.0 |
Endorphins/*pharmacology | 2 | 25.0 |
Cerebral Cortex/metabolism | 3 | 4.0 |
Feeding Behavior/drug effects | 3 | 23.0 |
Drug Combinations | 2 | 0.0 |
Mesocricetus | 2 | 1.0 |
Spinal Cord/drug effects | 2 | 100.0 |
Nerve Tissue Proteins/pharmacology | 2 | 4.0 |
Intestines/analysis | 2 | 40.0 |
Binding Sites, Antibody | 2 | 0.0 |
Cholecystokinin/*blood/immunology | 3 | 100.0 |
Peptides/*pharmacology | 2 | 0.0 |
Sex Characteristics | 2 | 0.0 |
Corn Oil | 2 | 40.0 |
Gallbladder/physiopathology | 3 | 100.0 |
Anemia, Pernicious/metabolism | 2 | 100.0 |
Duodenum/analysis | 4 | 33.0 |
Gastrins/*analysis/metabolism/physiology | 2 | 100.0 |
Jejunum/analysis | 3 | 42.0 |
Peptic Ulcer/metabolism | 2 | 100.0 |
Pyloric Antrum/analysis | 2 | 100.0 |
Sulfates/analysis | 2 | 50.0 |
Tyrosine/analysis | 2 | 33.0 |
Zollinger-Ellison Syndrome/metabolism | 3 | 100.0 |
Cell Fusion | 2 | 0.0 |
Cell Membrane/physiology | 2 | 1.0 |
Endoplasmic Reticulum/metabolism | 2 | 0.0 |
Oligopeptides/physiology | 2 | 18.0 |
Pancreatic Hormones/*genetics/secretion | 2 | 100.0 |
Prostaglandins/metabolism | 2 | 11.0 |
Steroids/physiology | 2 | 22.0 |
Amino Acids/*administration & dosage | 2 | 33.0 |
Radioimmunoassay/*methods | 2 | 2.0 |
Sincalide | 2 | 50.0 |
Ethanolamines/pharmacology | 2 | 33.0 |
Dementia/*metabolism | 2 | 11.0 |
Huntington Disease/*metabolism | 2 | 20.0 |
Rabbits/immunology | 2 | 2.0 |
Hexamethonium Compounds/pharmacology | 2 | 50.0 |
Tetrodotoxin/pharmacology | 2 | 5.0 |
Cholecystography | 2 | 100.0 |
Gastric Juice/secretion | 2 | 50.0 |
Enzyme-Linked Immunosorbent Assay | 2 | 0.0 |
Trans-Activation (Genetics) | 2 | 0.0 |
Tyrosine/metabolism | 2 | 0.0 |
